2020
Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics
Steinman JB, Lum FM, Ho PP, Kaminski N, Steinman L. Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 24620-24626. PMID: 32883878, PMCID: PMC7547272, DOI: 10.1073/pnas.2012358117.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptorT helper 2 (Th2) immune responsesCross-reactive humoral immunityCOVID-19T cell immunityT helper 2SARS-CoV-2Cell immunityCommon coronavirusesHelper 2Humoral immunityInflammatory cytokinesRespiratory tractImmune responseCommon coldPandemic virusPotential therapeuticsChildrenPathogenesisImmunityReduced developmentMolecular checkpointsCoronavirusLow levelsEosinophiliaSummary and Future Applications of Precision Medicine in Pulmonary, Critical Care, and Sleep Medicine
Gomez J, Kaminski N, Himes B. Summary and Future Applications of Precision Medicine in Pulmonary, Critical Care, and Sleep Medicine. Respiratory Medicine 2020, 417-428. DOI: 10.1007/978-3-030-31507-8_28.Peer-Reviewed Original ResearchCritical careSleep medicinePrecision medicine strategiesNovel biomarker candidatesDisease endotypesClinical studiesDisease pathogenesisHealthcare providersNovel interventionsBiomarker candidatesMedicine strategiesPrecision medicineDrug targetsCareMolecular underpinningsWidespread implementationMedicineEndotypesPulmonaryPathogenesisCohortInitial discoveryBiomarkers
2018
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?
Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, Richeldi L, Schwarz MI, Selman M, Wuyts WA, Schwartz DA. Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? The Lancet Respiratory Medicine 2018, 6: 154-160. PMID: 29413083, PMCID: PMC5903445, DOI: 10.1016/s2213-2600(18)30007-9.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisDevelopment of IPFFatal lung diseaseAlveolar epithelial cellsClinical presentationDistal airwaysLung diseaseFibroblast fociSubpleural fibrosisMicroscopic honeycombingPathogenic mechanismsFibrosisDiseaseEpithelial cellsMolecular mechanismsAirwayPathogenesisHoneycombingCentral driver
2007
Approaching the degradome in idiopathic pulmonary fibrosis
Pardo A, Selman M, Kaminski N. Approaching the degradome in idiopathic pulmonary fibrosis. The International Journal Of Biochemistry & Cell Biology 2007, 40: 1141-1155. PMID: 18207447, DOI: 10.1016/j.biocel.2007.11.020.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisIPF lungsProgressive fibrosisEpithelial injuryUnknown etiologyLung disordersBody of evidenceLung fibrogenesisLung parenchymaAbnormal remodelingExaggerated accumulationFibrosisSignificant upregulationExtracellular matrixLungCritical roleGene expression studiesFoci formationGlobal gene expression studiesFibrogenesisPathogenesisInjuryEtiologyParenchyma
2004
Increase in p21 expression independent of the p53 pathway in bleomycin-induced lung fibrosis
Blundell R, Kaminski N, Harrison D. Increase in p21 expression independent of the p53 pathway in bleomycin-induced lung fibrosis. Experimental And Molecular Pathology 2004, 77: 231-237. PMID: 15507241, DOI: 10.1016/j.yexmp.2004.07.003.Peer-Reviewed Original ResearchConceptsP21 expressionLung fibrosisFibrotic lungsAnimal mouse modelsNuclear p21 expressionCytoplasmic p21 expressionExpression of p21Bleomycin injectionLung diseaseMouse modelAnimal modelsImmuno-histochemistryDay 14P27 expressionCell cycle regulatory genesBleomycin inductionFibrosisLungBleomycinP53 pathwayP53Gene expression analysisExpressionPCNAPathogenesisThe mechanisms of idiopathic pulmonary fibrosis: can we see the elephant?
Gibson K, Kaminski N. The mechanisms of idiopathic pulmonary fibrosis: can we see the elephant? Drug Discovery Today Disease Mechanisms 2004, 1: 117-122. DOI: 10.1016/j.ddmec.2004.08.002.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisPulmonary fibrosisNew therapeutic interventionsTherapeutic interventionsPathogenesis of IPFEarly-stage diseaseChronic respiratory illnessColorado Health Sciences CenterPotential new therapiesNew vessel formationNovel disease mechanismsHealth Sciences CenterMatrix metalloprotease activationStage diseaseRespiratory illnessEffective therapyLung tissueNew therapiesAnimal modelsDisease pathogenesisFibrosisPathogenesisMetalloprotease activationDisease mechanismsVessel formation